Notify me when Innovative Cellular Therapeutics Holdings Ltd files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | Common Stock, par value $0.0001 | 9.8% | $30.9M | 1.9M | Innovative Cellular Therapeutics Holdings Ltd | 06 Nov 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|